217 related articles for article (PubMed ID: 1744111)
1. Structure-activity relationships of interleukin-8 determined using chemically synthesized analogs. Critical role of NH2-terminal residues and evidence for uncoupling of neutrophil chemotaxis, exocytosis, and receptor binding activities.
Clark-Lewis I; Schumacher C; Baggiolini M; Moser B
J Biol Chem; 1991 Dec; 266(34):23128-34. PubMed ID: 1744111
[TBL] [Abstract][Full Text] [Related]
2. Structural requirements for interleukin-8 function identified by design of analogs and CXC chemokine hybrids.
Clark-Lewis I; Dewald B; Loetscher M; Moser B; Baggiolini M
J Biol Chem; 1994 Jun; 269(23):16075-81. PubMed ID: 8206907
[TBL] [Abstract][Full Text] [Related]
3. Amino-terminal processing of chemokine ENA-78 regulates biological activity.
Nufer O; Corbett M; Walz A
Biochemistry; 1999 Jan; 38(2):636-42. PubMed ID: 9888803
[TBL] [Abstract][Full Text] [Related]
4. Neutrophil activation by monomeric interleukin-8.
Rajarathnam K; Sykes BD; Kay CM; Dewald B; Geiser T; Baggiolini M; Clark-Lewis I
Science; 1994 Apr; 264(5155):90-2. PubMed ID: 8140420
[TBL] [Abstract][Full Text] [Related]
5. Chemical synthesis, purification, and characterization of two inflammatory proteins, neutrophil activating peptide 1 (interleukin-8) and neutrophil activating peptide.
Clark-Lewis I; Moser B; Walz A; Baggiolini M; Scott GJ; Aebersold R
Biochemistry; 1991 Mar; 30(12):3128-35. PubMed ID: 2007144
[TBL] [Abstract][Full Text] [Related]
6. Receptor recognition and specificity of interleukin-8 is determined by residues that cluster near a surface-accessible hydrophobic pocket.
Hammond ME; Shyamala V; Siani MA; Gallegos CA; Feucht PH; Abbott J; Lapointe GR; Moghadam M; Khoja H; Zakel J; Tekamp-Olson P
J Biol Chem; 1996 Apr; 271(14):8228-35. PubMed ID: 8626516
[TBL] [Abstract][Full Text] [Related]
7. Structural requirements of platelet chemokines for neutrophil activation.
Yan Z; Zhang J; Holt JC; Stewart GJ; Niewiarowski S; Poncz M
Blood; 1994 Oct; 84(7):2329-39. PubMed ID: 7919350
[TBL] [Abstract][Full Text] [Related]
8. Binding to heparan sulfate or heparin enhances neutrophil responses to interleukin 8.
Webb LM; Ehrengruber MU; Clark-Lewis I; Baggiolini M; Rot A
Proc Natl Acad Sci U S A; 1993 Aug; 90(15):7158-62. PubMed ID: 8346230
[TBL] [Abstract][Full Text] [Related]
9. Design and evaluation of small peptides mapping the exposed surface of IL-8.
Thompson SK; Veber DF; Jurewicz AJ; Peishoff CE; Lee JM; White JR
Int J Pept Protein Res; 1996 Mar; 47(3):214-8. PubMed ID: 8740972
[TBL] [Abstract][Full Text] [Related]
10. Matrix Metalloproteinase-9-Generated COOH-, but Not NH
Gouwy M; De Buck M; Abouelasrar Salama S; Vandooren J; Knoops S; Pörtner N; Vanbrabant L; Berghmans N; Opdenakker G; Proost P; Van Damme J; Struyf S
Front Immunol; 2018; 9():1081. PubMed ID: 29915572
[TBL] [Abstract][Full Text] [Related]
11. Truncation of CXCL8 to CXCL8(9-77) enhances actin polymerization and in vivo migration of neutrophils.
Metzemaekers M; Vandendriessche S; Berghmans N; Gouwy M; Proost P
J Leukoc Biol; 2020 Jun; 107(6):1167-1173. PubMed ID: 32272490
[TBL] [Abstract][Full Text] [Related]
12. Construction, purification and biological activities of recombinant human interleukin-2 analogs.
Boone T; Chazin V; Kenney W; Swanson E; Altrock B
Dev Biol Stand; 1988; 69():157-68. PubMed ID: 3066670
[TBL] [Abstract][Full Text] [Related]
13. NH2- and COOH-terminal truncations of murine granulocyte chemotactic protein-2 augment the in vitro and in vivo neutrophil chemotactic potency.
Wuyts A; D'Haese A; Cremers V; Menten P; Lenaerts JP; De Loof A; Heremans H; Proost P; Van Damme J
J Immunol; 1999 Dec; 163(11):6155-63. PubMed ID: 10570306
[TBL] [Abstract][Full Text] [Related]
14. A synthetic peptide which specifically inhibits heat-treated interleukin-8 binding and chemotaxis for neutrophils.
Miller EJ; Kurdowska A; Nagao S; Carr FK; Hayashi S; Atkinson MA; Cohen AB
Agents Actions; 1993 Nov; 40(3-4):200-8. PubMed ID: 8023744
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-8 antagonists generated by N-terminal modification.
Moser B; Dewald B; Barella L; Schumacher C; Baggiolini M; Clark-Lewis I
J Biol Chem; 1993 Apr; 268(10):7125-8. PubMed ID: 8463247
[TBL] [Abstract][Full Text] [Related]
16. Endothelial and leukocyte forms of IL-8. Conversion by thrombin and interactions with neutrophils.
Hébert CA; Luscinskas FW; Kiely JM; Luis EA; Darbonne WC; Bennett GL; Liu CC; Obin MS; Gimbrone MA; Baker JB
J Immunol; 1990 Nov; 145(9):3033-40. PubMed ID: 2212672
[TBL] [Abstract][Full Text] [Related]
17. Interleukin 8 dimerization as a mechanism for regulation of neutrophil adherence-dependent oxidant production.
Williams MA; Cave CM; Quaid G; Robinson C; Daly TJ; Witt D; Lentsch AB; Solomkin JS
Shock; 2005 Apr; 23(4):371-6. PubMed ID: 15803062
[TBL] [Abstract][Full Text] [Related]
18. Platelet factor 4 binds to interleukin 8 receptors and activates neutrophils when its N terminus is modified with Glu-Leu-Arg.
Clark-Lewis I; Dewald B; Geiser T; Moser B; Baggiolini M
Proc Natl Acad Sci U S A; 1993 Apr; 90(8):3574-7. PubMed ID: 8475106
[TBL] [Abstract][Full Text] [Related]
19. The Positively Charged COOH-terminal Glycosaminoglycan-binding CXCL9(74-103) Peptide Inhibits CXCL8-induced Neutrophil Extravasation and Monosodium Urate Crystal-induced Gout in Mice.
Vanheule V; Janssens R; Boff D; Kitic N; Berghmans N; Ronsse I; Kungl AJ; Amaral FA; Teixeira MM; Van Damme J; Proost P; Mortier A
J Biol Chem; 2015 Aug; 290(35):21292-304. PubMed ID: 26183778
[TBL] [Abstract][Full Text] [Related]
20. Synthetic hexa- and heptapeptides that inhibit IL-8 from binding to and activating human blood neutrophils.
Hayashi S; Kurdowska A; Miller EJ; Albright ME; Girten BE; Cohen AB
J Immunol; 1995 Jan; 154(2):814-24. PubMed ID: 7814885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
